Health Care · Surgical & Medical Instruments & Apparatus · Nasdaq · CIK 1275187 · FYE May 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $14.77Day +0.96%Mkt cap $610M1Y +64.8%Off 52W high −2.8%Vol (1Y) 43.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,294 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest3.2% of sh out |
| Days to cover2.2d |
| 13F net flow (QoQ)−0.46% |
| Top-10 13F concentration53.3% |
| Next report (est.)2026-10-15 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$320.2M |
| Earnings (TTM)-$36.7M |
| ROE−17.5% |
| Net margin−11.6% |
| ROIC−24.6% |
| Sales growth 3Y−2.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+15.0% |
| 1Y+64.8% |
| 3Y+70.0% |
| 5Y−44.5% |
| 10Y−10.6% |
| Since incept. (ann.)−2.6% |
Total return through 2026-07-30 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)43.7% |
| Ann. volatility (3Y)56.7% |
| Sharpe (1Y)1.34 |
| Sharpe (3Y)0.59 |
| Max drawdown (1Y)−28.9% |
| Max drawdown (3Y)−40.7% |
| Beta (3Y vs SPY)0.39 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 3.7M | $42M | 8.92% | −4.5% |
| Point72 Asset Management, L.P. | 3.2M | $36M | 7.70% | +12.6% |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | 2.5M | $28M | 5.94% | −2.0% |
| Broadfin Holdings LLC | 2.1M | $24M | 5.01% | new |
| ARMISTICE CAPITAL, LLC | 1.9M | $21M | 4.52% | +9.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7M | $20M | 4.18% | new |
| ROYCE & ASSOCIATES LP | 1.5M | $17M | 3.70% | +20.6% |
| WEBER CAPITAL MANAGEMENT LLC /ADV | 1.4M | $16M | 3.32% | −1.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-05-31 | 2026-07-14 | — | — | $86.6M | +8.0% |
| 2026-02-28 | 2026-04-02 | −$0.19 | — | $78.4M | +8.9% |
| 2025-11-30 | 2026-01-06 | −$0.15 | — | $79.4M | +9.0% |
| 2025-08-31 | 2025-10-02 | −$0.26 | — | $75.7M | +12.2% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-15 is ESTIMATED from filing cadence (median gap 93d) — not company-confirmed.
Med Device 53% · Med Tech 47%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
